Helping push continued advancements
Del Re hopes that her work with liquid biopsies as companion diagnostics to monitor the effectiveness of treatments will help advance personalized cancer treatment and improve outcomes even more.
By identifying whether a patient’s cancer has become resistant to a specific therapy, or whether they are not responding to first line therapy, clinicians can make better informed decisions about additional therapy, she says.
Del Re works with the QIAcuity Digital PCR System because it is automated and enables her to obtain results quickly enough. Sample preparation for digital droplet PCR, for example, requires many steps and consequently, “the risk of incurring errors from operators is quite high,” she adds.
This use case of a liquid biopsy as a companion diagnostic has yet to be standard clinical practice - it is still in the research phases. At her institution in Pisa, however, “clinicians believe in it and ask for it,” she says. But she must work with them in an interdisciplinary fashion to help them understand and interpret results.
On the patient side, this means hope for a future with faster diagnosis, but it is still a shocking journey no matter what. How did Battarola cope, for example? After her diagnosis, Battarola consulted a professional “support coach.” The coach helped her remain calm before her surgery and taught her to focus on the positive things in her life, she says.
“He helped me learn to enjoy what I have every single day, my house, food and my daughter. Sometimes we forget this,” she says. During her treatment, she also consulted an oncology nutritionist, a homeopathic doctor and an osteopath, who all contributed to a holistic treatment plan. She also meditated every day, she says.
She is still taking olaparib as maintenance therapy to keep the cancer from returning.
“I’m working on my faith,” she says, but she is not referring to religion. “It’s the engine of life and helps people live in the present. My plan for the future is to enjoy every day of my life.”